Neuronetics Operating Income vs Cost Of Revenue Analysis

STIM Stock

USD 2.42 0.07 2.98%

Neuronetics financial indicator trend analysis is infinitely more than just investigating Neuronetics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neuronetics is a good investment. Please check the relationship between Neuronetics Operating Income and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

Operating Income vs Cost Of Revenue

Operating Income vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neuronetics Operating Income account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Neuronetics' Operating Income and Cost Of Revenue is -0.87. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Neuronetics, assuming nothing else is changed. The correlation between historical values of Neuronetics' Operating Income and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Neuronetics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Operating Income i.e., Neuronetics' Operating Income and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.87

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Neuronetics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Neuronetics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Neuronetics income statement and represents the costs associated with goods and services Neuronetics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Neuronetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuronetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.As of the 23rd of January 2025, Selling General Administrative is likely to drop to about 19.4 M. In addition to that, Sales General And Administrative To Revenue is likely to drop to 0.26

	2024	2025 (projected)
Depreciation And Amortization	2.3M	1.4M
Interest Income	4.2M	3.3M

Depreciation And Amortization Interest Income

Neuronetics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets
Total Assets		0.67	0.72	0.63	0.97	0.55	0.97	0.84	0.83	-0.62	-0.87	0.9	0.95	0.87	0.87	0.43	0.69	0.95	0.72	0.95	0.93	0.6	-0.93	0.97	0.82	0.79
Short Long Term Debt Total	0.67		0.73	0.4	0.55	0.51	0.58	0.64	0.51	-0.02	-0.75	0.78	0.5	0.72	0.67	0.07	0.82	0.5	0.76	0.69	0.74	0.65	-0.48	0.68	0.77	0.78
Other Current Liab	0.72	0.73		0.86	0.64	0.23	0.67	0.75	0.41	-0.15	-0.81	0.62	0.56	0.71	0.65	-0.08	0.61	0.56	0.82	0.76	0.81	0.33	-0.63	0.76	0.88	0.74
Total Current Liabilities	0.63	0.4	0.86		0.63	0.21	0.63	0.78	0.43	-0.27	-0.68	0.48	0.52	0.61	0.56	-0.02	0.32	0.53	0.61	0.67	0.71	0.13	-0.67	0.67	0.69	0.55
Total Stockholder Equity	0.97	0.55	0.64	0.63		0.57	1.0	0.83	0.84	-0.66	-0.84	0.87	0.95	0.81	0.8	0.37	0.63	0.95	0.67	0.94	0.89	0.62	-0.99	0.96	0.73	0.75
Other Liab	0.55	0.51	0.23	0.21	0.57		0.55	0.33	0.85	-0.61	-0.33	0.62	0.67	0.29	0.28	0.22	0.31	0.67	0.17	0.44	0.37	0.8	-0.55	0.47	0.18	0.26
Net Tangible Assets	0.97	0.58	0.67	0.63	1.0	0.55		0.84	0.82	-0.61	-0.87	0.88	0.94	0.83	0.81	0.35	0.68	0.94	0.72	0.96	0.91	0.63	-0.98	0.96	0.75	0.79
Property Plant And Equipment Net	0.84	0.64	0.75	0.78	0.83	0.33	0.84		0.62	-0.28	-0.89	0.8	0.67	0.95	0.91	0.38	0.61	0.68	0.74	0.89	0.96	0.38	-0.83	0.9	0.87	0.8
Current Deferred Revenue	0.83	0.51	0.41	0.43	0.84	0.85	0.82	0.62		-0.74	-0.61	0.76	0.9	0.6	0.63	0.51	0.48	0.91	0.42	0.75	0.65	0.74	-0.8	0.74	0.48	0.53
Net Debt	-0.62	-0.02	-0.15	-0.27	-0.66	-0.61	-0.61	-0.28	-0.74		0.2	-0.42	-0.81	-0.26	-0.32	-0.49	0.04	-0.81	0.04	-0.41	-0.34	-0.36	0.66	-0.52	-0.17	-0.05
Retained Earnings	-0.87	-0.75	-0.81	-0.68	-0.84	-0.33	-0.87	-0.89	-0.61	0.2		-0.79	-0.7	-0.91	-0.88	-0.25	-0.83	-0.71	-0.92	-0.96	-0.94	-0.53	0.8	-0.89	-0.92	-0.94
Accounts Payable	0.9	0.78	0.62	0.48	0.87	0.62	0.88	0.8	0.76	-0.42	-0.79		0.82	0.82	0.77	0.28	0.78	0.82	0.71	0.87	0.87	0.64	-0.83	0.89	0.7	0.8
Cash	0.95	0.5	0.56	0.52	0.95	0.67	0.94	0.67	0.9	-0.81	-0.7	0.82		0.68	0.7	0.43	0.54	1.0	0.54	0.85	0.76	0.62	-0.91	0.87	0.61	0.62
Non Current Assets Total	0.87	0.72	0.71	0.61	0.81	0.29	0.83	0.95	0.6	-0.26	-0.91	0.82	0.68		0.99	0.5	0.71	0.69	0.77	0.89	0.97	0.41	-0.77	0.91	0.92	0.85
Non Currrent Assets Other	0.87	0.67	0.65	0.56	0.8	0.28	0.81	0.91	0.63	-0.32	-0.88	0.77	0.7	0.99		0.62	0.66	0.71	0.71	0.87	0.93	0.4	-0.75	0.89	0.9	0.8
Other Assets	0.43	0.07	-0.08	-0.02	0.37	0.22	0.35	0.38	0.51	-0.49	-0.25	0.28	0.43	0.5	0.62		0.07	0.44	-0.01	0.32	0.34	0.08	-0.31	0.36	0.28	0.17
Long Term Debt	0.69	0.82	0.61	0.32	0.63	0.31	0.68	0.61	0.48	0.04	-0.83	0.78	0.54	0.71	0.66	0.07		0.55	0.92	0.81	0.72	0.6	-0.55	0.67	0.71	0.95
Cash And Short Term Investments	0.95	0.5	0.56	0.53	0.95	0.67	0.94	0.68	0.91	-0.81	-0.71	0.82	1.0	0.69	0.71	0.44	0.55		0.54	0.85	0.77	0.62	-0.92	0.88	0.62	0.63
Net Receivables	0.72	0.76	0.82	0.61	0.67	0.17	0.72	0.74	0.42	0.04	-0.92	0.71	0.54	0.77	0.71	-0.01	0.92	0.54		0.87	0.81	0.45	-0.62	0.74	0.84	0.97
Common Stock Total Equity	0.95	0.69	0.76	0.67	0.94	0.44	0.96	0.89	0.75	-0.41	-0.96	0.87	0.85	0.89	0.87	0.32	0.81	0.85	0.87		0.95	0.6	-0.91	0.95	0.86	0.92
Common Stock Shares Outstanding	0.93	0.74	0.81	0.71	0.89	0.37	0.91	0.96	0.65	-0.34	-0.94	0.87	0.76	0.97	0.93	0.34	0.72	0.77	0.81	0.95		0.51	-0.88	0.97	0.93	0.86
Long Term Debt Total	0.6	0.65	0.33	0.13	0.62	0.8	0.63	0.38	0.74	-0.36	-0.53	0.64	0.62	0.41	0.4	0.08	0.6	0.62	0.45	0.6	0.51		-0.59	0.58	0.4	0.51
Non Current Liabilities Total	-0.93	-0.48	-0.63	-0.67	-0.99	-0.55	-0.98	-0.83	-0.8	0.66	0.8	-0.83	-0.91	-0.77	-0.75	-0.31	-0.55	-0.92	-0.62	-0.91	-0.88	-0.59		-0.94	-0.69	-0.69
Capital Surpluse	0.97	0.68	0.76	0.67	0.96	0.47	0.96	0.9	0.74	-0.52	-0.89	0.89	0.87	0.91	0.89	0.36	0.67	0.88	0.74	0.95	0.97	0.58	-0.94		0.87	0.8
Inventory	0.82	0.77	0.88	0.69	0.73	0.18	0.75	0.87	0.48	-0.17	-0.92	0.7	0.61	0.92	0.9	0.28	0.71	0.62	0.84	0.86	0.93	0.4	-0.69	0.87		0.85
Other Current Assets	0.79	0.78	0.74	0.55	0.75	0.26	0.79	0.8	0.53	-0.05	-0.94	0.8	0.62	0.85	0.8	0.17	0.95	0.63	0.97	0.92	0.86	0.51	-0.69	0.8	0.85

Click cells to compare fundamentals

Neuronetics Account Relationship Matchups

Neuronetics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	78.7M	141.2M	116.9M	115.8M	133.2M	100.9M
Short Long Term Debt Total	38.3M	39.5M	39.7M	62.5M	71.8M	44.7M
Other Current Liab	6.0M	6.9M	13.4M	10.9M	12.6M	9.3M
Total Current Liabilities	13.7M	15.7M	33.2M	19.8M	22.8M	20.5M
Total Stockholder Equity	25.5M	85.2M	57.1M	34.2M	39.3M	41.3M
Other Liab	2.1M	1.7M	1.5M	829K	746.1K	1.2M
Net Tangible Assets	46.7M	25.5M	85.2M	57.1M	65.6M	68.9M
Property Plant And Equipment Net	4.1M	5.1M	5.3M	4.8M	5.5M	3.9M
Current Deferred Revenue	2.0M	2.5M	2.0M	1.6M	1.9M	2.2M
Net Debt	(10.6M)	(54.6M)	(30.6M)	2.8M	2.5M	2.6M
Retained Earnings	(277.5M)	(308.7M)	(345.9M)	(376.1M)	(338.5M)	(355.4M)
Accounts Payable	3.7M	4.3M	2.4M	4.8M	5.5M	3.8M
Cash	49.0M	94.1M	70.3M	59.7M	68.6M	68.7M
Non Current Assets Total	13.6M	25.9M	18.1M	22.0M	25.3M	13.4M
Non Currrent Assets Other	7.2M	19.1M	11.6M	12.4M	14.3M	7.9M
Other Assets	12.9M	167.1M	9.2M	1.0	1.15	1.09
Long Term Debt	34.6M	35.3M	22.8M	59.3M	68.2M	71.6M
Cash And Short Term Investments	50.8M	96.3M	71.9M	60.6M	69.7M	69.7M
Net Receivables	7.2M	7.8M	13.8M	17.8M	20.5M	21.5M
Common Stock Total Equity	177K	186K	191K	273K	314.0K	329.6K
Common Stock Shares Outstanding	18.8M	25.5M	26.9M	28.7M	33.0M	17.5M
Long Term Debt Total	30.4M	19.9M	34.6M	22.8M	26.3M	28.2M
Liabilities And Stockholders Equity	78.7M	141.2M	116.9M	115.8M	133.2M	100.9M
Non Current Liabilities Total	39.5M	40.3M	26.6M	61.8M	55.6M	63.4M
Capital Surpluse	291.9M	297.8M	302.8M	402.7M	463.1M	238.9M
Inventory	3.7M	6.6M	8.9M	8.1M	9.3M	5.0M
Other Current Assets	3.3M	4.6M	4.2M	7.3M	8.4M	8.8M
Other Stockholder Equity	302.8M	393.6M	402.7M	410.0M	471.5M	274.4M
Total Liab	53.2M	56.0M	59.8M	81.6M	73.5M	78.2M
Property Plant And Equipment Gross	4.1M	5.1M	5.3M	7.6M	8.7M	9.2M
Total Current Assets	65.0M	115.3M	98.8M	93.8M	107.9M	87.4M
Short Term Debt	1.2M	1.3M	14.8M	1.7M	1.5M	1.4M
Common Stock	191K	264K	273K	291K	334.7K	190.6K
Property Plant Equipment	4.9M	730K	5.1M	2.0M	2.3M	2.7M
Net Invested Capital	60.1M	120.5M	93.0M	93.5M	107.5M	60.4M
Net Working Capital	51.3M	99.6M	65.6M	74.0M	85.1M	75.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:

How To Invest In Neuronetics

Details

Is Neuronetics Stock a good investment?

Details

What is Neuronetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.28)

Revenue Per Share

2.453

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.17)

Return On Equity

(1.00)

The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neuronetics Operating Income vs Cost Of Revenue Analysis

Operating Income vs Cost Of Revenue

Operating Income vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Operating Income

Cost Of Revenue

Neuronetics fundamental ratios Correlations

Neuronetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neuronetics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Total Stockholder Equity	+ 0.97	Total Assets
Net Tangible Assets	+ 0.97	Total Assets
Capital Surpluse	+ 0.97	Total Assets

Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Common Stock Total Equity	- 0.96	Retained Earnings
Capital Surpluse	- 0.94	Non Current Liabilities Total
Other Current Assets	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.94	Retained Earnings